# GenInherit-LLM: Research & Development Specification
## Volume 4: Inference Reasoning Engine and Clinical Workflows

```text
====================================================================================================
  GENINHERIT-LLM: TECHNICAL RESEARCH & DEVELOPMENT SPECIFICATION
  VOLUME 4: INFERENCE REASONING ENGINE AND CLINICAL WORKFLOWS
====================================================================================================
  CONTINUALLY EVOLVING FAMILY-SPECIFIC GENOMIC INHERITANCE REASONING LARGE LANGUAGE MODEL
  INFERENCE ENGINE ARCHITECTURE, CLINICAL REASONING TRACES, AND WORKFLOW INTEGRATION
  SYSTEM TARGET: MULTIGENERATIONAL DEDUCTIVE GENOMICS
====================================================================================================
```

---

## Document Overview and Metadata

* **Document Title:** GenInherit-LLM Technical R&D Specification — Volume 4: Inference Reasoning Engine and Clinical Workflows
* **Document Number:** GIN-SPEC-2026-VOL4
* **Target Audience:** Clinical Geneticists, Bioinformaticians, Clinical Informatics Engineers, Medical AI Researchers
* **Primary Scope:** Autoregressive deductive inference engines, prompt engineering protocols, 10-tier structured clinical output schemas, complex inheritance reasoning traces, ethical disease-risk boundaries, and institutional clinical workflow integrations.

---

## Table of Contents

1. [The Inference Engine Architecture](#1-the-inference-engine-architecture)
2. [The Four Core Clinical Reasoning Functions](#2-the-four-core-clinical-reasoning-functions)
3. [Input Architecture and Dynamic Context Assembly](#3-input-architecture-and-dynamic-context-assembly)
4. [Standardized 10-Component Output Schema](#4-standardized-10-component-output-schema)
5. [The Formal Deductive Reasoning Chain](#5-the-formal-deductive-reasoning-chain)
6. [Deep-Dive Clinical Case Study 1: Multigenerational Paternal Transmission](#6-deep-dive-clinical-case-study-1-multigenerational-paternal-transmission)
7. [Deep-Dive Clinical Case Study 2: Autosomal Recessive Carrier Tracing and Consanguinity](#7-deep-dive-clinical-case-study-2-autosomal-recessive-carrier-tracing-and-consanguinity)
8. [Deep-Dive Clinical Case Study 3: X-Linked Transmission and Skewed Lyonization](#8-deep-dive-clinical-case-study-3-x-linked-transmission-and-skewed-lyonization)
9. [Deep-Dive Clinical Case Study 4: De Novo Mutation Discrimination](#9-deep-dive-clinical-case-study-4-de-novo-mutation-discrimination)
10. [Deep-Dive Clinical Case Study 5: Resolving Conflicting Laboratory Reports](#10-deep-dive-clinical-case-study-5-resolving-conflicting-laboratory-reports)
11. [Deep-Dive Clinical Case Study 6: Epistemic Management of Missing Family Members](#11-deep-dive-clinical-case-study-6-epistemic-management-of-missing-family-members)
12. [Ethical Disease-Risk Boundaries and Penetrance Non-Determinism](#12-ethical-disease-risk-boundaries-and-penetrance-non-determinism)
13. [Epistemic Vocabulary Enforcement: Observed vs. Inferred vs. Unknown](#13-epistemic-vocabulary-enforcement-observed-vs-inferred-vs-unknown)
14. [Institutional Clinical Workflow Integration](#14-institutional-clinical-workflow-integration)
15. [Academic Research and Cohort Simulation Workflow](#15-academic-research-and-cohort-simulation-workflow)
16. [Medical Education and Student Sandbox Protocol](#16-medical-education-and-student-sandbox-protocol)
17. [The Family-Mediated Interface Protocol](#17-the-family-mediated-interface-protocol)
18. [End-to-End System Processing Flowchart](#18-end-to-end-system-processing-flowchart)

---

## 1. The Inference Engine Architecture

The GenInherit-LLM inference engine converts clinical queries into verified, multi-hop biological deductions through a tightly orchestrated, air-gapped pipeline:

```text
====================================================================================================
                        INFERENCE ENGINE PIPELINE TOPOLOGY
====================================================================================================

      CLINICAL USER QUERY (Genetic Counselor / Physician)
              |
              v
      +-------------------------------------------------------------------+
      | 1. AUTHENTICATION & ACCESS CONTROL GATEWAY                         |
      |    • Validate mTLS certificate, JWT bearer token, and RBAC role.  |
      |    • Check user authorization against requested Family ID.        |
      +-------------------------------------------------------------------+
              |
              v
      +-------------------------------------------------------------------+
      | 2. CONTEXT ASSEMBLER & TOKENIZER                                  |
      |    • Construct prompt: System Directive + Active Pedigree Graph   |
      |      + Certified Variant Ledger + Longitudinal Phenotype History. |
      |    • Inject PSTS-v1 specialized structural tokens.                |
      +-------------------------------------------------------------------+
              |
              v
      +-------------------------------------------------------------------+
      | 3. MULTI-TENANT ADAPTER DISPATCHER                                |
      |    • Match Family ID to encrypted adapter snapshot on NVMe storage|
      |    • Hot-swap low-rank weights into GPU memory (< 35 ms latency). |
      +-------------------------------------------------------------------+
              |
              v
      +-------------------------------------------------------------------+
      | 4. NEURAL TRANSFORMER EXECUTION (DGX B200)                        |
      |    • Forward pass through Frozen 7B Base + Family-Specific LoRA.  |
      |    • Constrained decoding with greedy/low-temperature sampling    |
      |      (Temperature: 0.15, Top-p: 0.90, Repetition Penalty: 1.15).  |
      +-------------------------------------------------------------------+
              |
              v
      +-------------------------------------------------------------------+
      | 5. OUTPUT GRAMMAR VALIDATOR & SAFETY FILTER                       |
      |    • Enforce strict 10-tier structured JSON/Markdown schema.      |
      |    • Verify epistemic vocabulary tags (OBSERVED vs. INFERRED).    |
      |    • Assert zero autonomous diagnostic claims.                    |
      +-------------------------------------------------------------------+
              |
              v
      +-------------------------------------------------------------------+
      | 6. AUDIT REGISTRY & SECURE TRANSMISSION                           |
      |    • Log query hash, execution time, and adapter version to WORM. |
      |    • Transmit validated clinical proof to attending clinician.    |
      +-------------------------------------------------------------------+
```

---

## 2. The Four Core Clinical Reasoning Functions

The inference engine executes four distinct cognitive operations across family lineages:

```text
+--------------------------------------------------------------------------------------------------+
|                            THE FOUR COGNITIVE CLINICAL OPERATIONS                                |
+--------------------------------------------------------------------------------------------------+

  FUNCTION 1: DETERMINISTIC FAMILY KNOWLEDGE RECALL
  --------------------------------------------------
  • Clinical Intent: Querying documented molecular findings for a specific relative.
  • Sample Query: "What molecular findings and zygosity are certified for Paternal Grandfather [I-1]?"
  • Cognitive Target: Exact recall from internalized low-rank parametric memory without hallucinations.

  FUNCTION 2: TOPOLOGICAL FAMILY MAPPING
  --------------------------------------
  • Clinical Intent: Tracing the spatial distribution of a variant across the pedigree.
  • Sample Query: "Enumerate all confirmed carriers of the LMNA c.1580G>T variant across Generations I-III."
  • Cognitive Target: Exhaustive enumeration of carrier, non-carrier, and untested family members.

  FUNCTION 3: DEDUCTIVE INHERITANCE REASONING
  -------------------------------------------
  • Clinical Intent: Establishing biological transmission pathways consistent with data.
  • Sample Query: "What inheritance mechanism and lineage pathway account for the proband's phenotype?"
  • Cognitive Target: Multi-hop Mendelian deduction, parent-of-origin resolution, obligate carrier identification.

  FUNCTION 4: CAUSAL EVIDENCE-LINKED EXPLANATION
  ----------------------------------------------
  • Clinical Intent: Providing an auditable biological rationale for a deduction.
  • Sample Query: "Why is maternal inheritance ruled out for the observed familial cardiomyopathy?"
  • Cognitive Target: Natural language clinical justification citing specific negative controls and lab tests.
+--------------------------------------------------------------------------------------------------+
```

---

## 3. Input Architecture and Dynamic Context Assembly

To guarantee determinism, prompts presented to the adapted model must adhere to a standardized contextual template:

```text
====================================================================================================
                        STANDARDIZED CLINICAL INFERENCE PROMPT
====================================================================================================
<SYSTEM_DIRECTIVE>
You are GenInherit-LLM (Instance: {FAMILY_ID}, Version: {ADAPTER_VERSION}).
You are an advanced clinical genomic reasoning assistant supporting board-certified geneticists.
You reason strictly over verified biological facts. You never invent individuals, variants, or 
phenotypes. When data is absent, you state STRICT_UNKNOWN. You distinguish OBSERVED laboratory 
facts from INFERRED mathematical deductions. You do not make autonomous medical diagnoses.
</SYSTEM_DIRECTIVE>

<PEDIGREE_STRUCTURE>
[PED_START] [FAM_ID:{FAMILY_ID}]
  [IND:I-1] [SEX:M] [PARENTS:NONE,NONE] [DEC:72]
  [IND:I-2] [SEX:F] [PARENTS:NONE,NONE] [DEC:80]
  [IND:II-1] [SEX:M] [PARENTS:I-1,I-2] [SPOUSE:II-2]
  [IND:II-2] [SEX:F] [PARENTS:NONE,NONE] [SPOUSE:II-1]
  [IND:III-1] [SEX:F] [PARENTS:II-1,II-2] [PROBAND]
[PED_END]
</PEDIGREE_STRUCTURE>

<CERTIFIED_VARIANT_LEDGER>
- IND:I-1  | GENE:MYBPC3 | HGVS:c.1504C>T | ZYGOSITY:HETEROZYGOUS | STATUS:VERIFIED_PRESENT | LAB:GeneDx_2018
- IND:II-1 | GENE:MYBPC3 | HGVS:c.1504C>T | ZYGOSITY:HETEROZYGOUS | STATUS:VERIFIED_PRESENT | LAB:Invitae_2022
- IND:II-2 | GENE:MYBPC3 | HGVS:c.1504C>T | ZYGOSITY:UNKNOWN      | STATUS:STRICT_UNKNOWN   | LAB:NONE
- IND:III-1| GENE:MYBPC3 | HGVS:c.1504C>T | ZYGOSITY:HETEROZYGOUS | STATUS:VERIFIED_PRESENT | LAB:Quest_2025
</CERTIFIED_VARIANT_LEDGER>

<LONGITUDINAL_PHENOTYPE_HISTORY>
- IND:I-1  | AGE:54 | HPO:HP:0001639 (Hypertrophic cardiomyopathy) | STATUS:CLINICIAN_CONFIRMED
- IND:II-1 | AGE:38 | HPO:HP:0001639 (Hypertrophic cardiomyopathy) | STATUS:CLINICIAN_CONFIRMED
- IND:III-1| AGE:12 | HPO:HP:0001639 (Mild left ventricular hypertrophy) | STATUS:CLINICIAN_CONFIRMED
</LONGITUDINAL_PHENOTYPE_HISTORY>

<CLINICAL_QUERY>
Deduce the biological transmission pathway of the MYBPC3 variant in Proband [III-1]. 
Identify obligate carriers, state the inheritance mechanism, and specify any critical testing gaps.
</CLINICAL_QUERY>
====================================================================================================
```

---

## 4. Standardized 10-Component Output Schema

To enforce clinical auditability, every response generated by GenInherit-LLM must conform to the following ten structural sections:

```text
+----+-----------------------------------------+---------------------------------------------------+
| #  | OUTPUT SCHEMA SECTION                   | FUNCTIONAL CONTENT & CLINICAL VALUE               |
+----+-----------------------------------------+---------------------------------------------------+
| 01 | RELEVANT FAMILY MEMBERS                 | Explicit enumeration of all individuals in trace. |
| 02 | CERTIFIED GENETIC FINDINGS              | Exact gene, HGVS cDNA/protein change, zygosity.   |
| 03 | INHERITANCE TRANSMISSION PATHWAY        | Lineage attribution (Paternal, Maternal, De Novo).|
| 04 | INHERITANCE MECHANISM CLASSIFICATION    | Formal pattern (AD, AR, XLR, XLD, MT, etc.).     |
| 05 | GENE-DISEASE VALIDITY ASSERTION         | ClinGen / OMIM disease validity classification.   |
| 06 | PHENOTYPIC CONCORDANCE SYNTHESIS        | Alignment between variant and documented HPO.     |
| 07 | LABORATORY PROVENANCE CITATIONS         | Explicit citation of CLIA lab reports and dates.  |
| 08 | EPISTEMIC UNCERTAINTY QUANTIFICATION    | Confidence estimation and mathematical bounds.    |
| 09 | CRITICAL MISSING INFORMATION / GAPS     | Untested individuals requiring targeted assays.   |
| 10 | HUMAN CLINICAL SIGN-OFF MANDATE         | SaMD disclaimer requiring geneticist review.      |
+----+-----------------------------------------+---------------------------------------------------+
```

---

## 5. The Formal Deductive Reasoning Chain

The internal reasoning sequence executed by the model across Transformer attention layers follows a strict biological progression:

```text
  [STEP 1: MOLECULAR VARIANT IDENTIFICATION]
  Extract locus, transcript, HGVS notation, and allelic state.
                    |
                    v
  [STEP 2: GENE & FUNCTIONAL ATTRIBUTION]
  Identify biological function, haploinsufficiency, or dominant-negative mechanism.
                    |
                    v
  [STEP 3: PEDIGREE GRAPH TRAVERSAL]
  Map individual nodes to biological parentage edges across generational tiers (G1 -> G2 -> G3).
                    |
                    v
  [STEP 4: MENDELIAN HYPOTHESIS TESTING]
  Evaluate compatibility with AD, AR, X-linked, and mitochondrial hypotheses.
                    |
                    v
  [STEP 5: LINEAGE ATTRIBUTION RESOLUTION]
  Trace transmitting alleles back to paternal or maternal founder chromosomes.
                    |
                    v
  [STEP 6: PHENOTYPIC PENETRANCE CONTEXTUALIZATION]
  Compare variant presence with age-dependent clinical onset across family members.
                    |
                    v
  [STEP 7: EPISTEMIC GAP & CONFLICT AUDITING]
  Assert STRICT_UNKNOWN for missing relatives; flag any conflicting lab interpretations.
                    |
                    v
  [STEP 8: EVIDENCE-LINKED SYNTHESIS]
  Emit natural language clinical proof with explicit laboratory citations.
```

---

## 6. Deep-Dive Clinical Case Study 1: Multigenerational Paternal Transmission

```text
====================================================================================================
CLINICAL CASE REPORT: FAM_CARDIO_001
====================================================================================================

CASE SUMMARY:
A 12-year-old female proband [III-1] presents with asymmetric septal hypertrophy. Familial testing 
reveals a heterozygous missense variant in MYBPC3 (c.1504C>T, p.Arg502Trp) in the proband, her 
father [II-1], and her paternal grandfather [I-1]. Paternal grandmother [I-2] is confirmed WT/WT. 
Mother [II-2] has not been genotyped.

MODEL REASONING GENERATION (VERBATIM):
----------------------------------------------------------------------------------------------------
1. RELEVANT FAMILY MEMBERS:
   - Paternal Grandfather [I-1] (Transmitting Ancestor)
   - Paternal Grandmother [I-2] (Negative Control)
   - Father [II-1] (Transmitting Parent)
   - Mother [II-2] (Untested Spouse)
   - Proband [III-1] (Presenting Patient)

2. CERTIFIED GENETIC FINDINGS:
   - Gene Symbol: MYBPC3 (Ensembl: ENSG00000134571)
   - Variant: NM_000256.3:c.1504C>T (p.Arg502Trp), GRCh38: chr11:47333013G>A
   - Zygosity: Heterozygous in [I-1], [II-1], and [III-1]

3. INHERITANCE TRANSMISSION PATHWAY:
   - Direct, uninterrupted transmission through the PATERNAL LINEAGE across three generations:
     Paternal Grandfather [I-1] ---> Father [II-1] ---> Proband [III-1].
   - Maternal transmission is considered highly improbable based on paternal molecular confirmation.

4. INHERITANCE MECHANISM CLASSIFICATION:
   - Autosomal Dominant (AD) with variable clinical expressivity.

5. GENE-DISEASE VALIDITY ASSERTION:
   - MYBPC3 is classified by ClinGen as having DEFINITIVE gene-disease validity for Familial 
     Hypertrophic Cardiomyopathy 4 (OMIM #115197).

6. PHENOTYPIC CONCORDANCE SYNTHESIS:
   - Concordance: HIGH. All three heterozygous carriers display phenotypic manifestations of 
     hypertrophic cardiomyopathy with onset ages of 54 (I-1), 38 (II-1), and 12 (III-1).
   - Demonstrates possible clinical anticipation or earlier diagnosis due to surveillance.

7. LABORATORY PROVENANCE CITATIONS:
   - [I-1]: GeneDx Molecular Lab #GDX-2018-994 (Sanger Sequencing, Verified 2018-04-11).
   - [II-1]: Invitae Cardiomyopathy Panel #INV-2022-108 (NGS 100x, Verified 2022-09-03).
   - [III-1]: Quest Diagnostics Genomic Health #QST-2025-441 (Targeted NGS, Verified 2025-01-19).

8. EPISTEMIC UNCERTAINTY QUANTIFICATION:
   - Transmission Lineage Confidence: > 99.8% Paternal Attribution.
   - Overall Mathematical Uncertainty: LOW (< 0.2%).

9. CRITICAL MISSING INFORMATION / GAPS:
   - Mother [II-2] is strictly UNTESTED. While paternal transmission is confirmed, targeted sequencing 
     of Mother [II-2] is recommended to exclude coincidental maternal carrier status (compound risk).

10. HUMAN CLINICAL SIGN-OFF MANDATE:
    - ATTENTION: This automated deduction is a clinical decision-support artifact and does NOT 
      constitute an autonomous medical diagnosis. Review by an ABMGG-certified geneticist is required.
----------------------------------------------------------------------------------------------------
```

---

## 7. Deep-Dive Clinical Case Study 2: Autosomal Recessive Carrier Tracing and Consanguinity

```text
====================================================================================================
CLINICAL CASE REPORT: FAM_RECESSIVE_042
====================================================================================================

PEDIGREE CONTEXT:
First-cousin consanguineous union (Father [II-1] and Mother [II-2] share grandparents [I-1, I-2]).
Proband [III-1] presents with severe developmental regression and microcephaly.

MODEL DEDUCTIVE REASONING (EXCERPT):
- Molecular Variant: ASPM NM_018136.5:c.3978G>A (p.Trp1326*), Homozygous in Proband [III-1].
- Paternal Genotype: Heterozygous Carrier (Verified).
- Maternal Genotype: Heterozygous Carrier (Verified).
- Common Ancestor Analysis: Both parents inherited the identical c.3978G>A allele from Grandfather [I-1],
  who is deduced to be an Obligate Ancestral Carrier with mathematical certainty P = 1.0.
- Inheritance Pattern: Autosomal Recessive (AR) secondary to Identity-by-Descent (IBD) consanguinity.
- Inbreeding Coefficient ($F$): Calculated pedigree $F = \frac{1}{16} = 0.0625$.
- Recurrence Risk for Future Offspring of II-1 and II-2: Exactly 25% (1 in 4) affected risk per pregnancy.
====================================================================================================
```

---

## 8. Deep-Dive Clinical Case Study 3: X-Linked Transmission and Skewed Lyonization

```text
====================================================================================================
CLINICAL CASE REPORT: FAM_XLINKED_088
====================================================================================================

PEDIGREE CONTEXT:
Male Proband [III-1], age 4, diagnosed with severe muscular dystrophy (DMD).
Mother [II-2] exhibits mild muscle weakness and elevated serum creatine kinase.
Father [II-1] is asymptomatic and genotypically wild-type.
Maternal Grandfather [I-1] died of heart failure at age 21 (Duchenne phenotype).

MODEL DEDUCTIVE REASONING (EXCERPT):
- Variant: DMD c.31_34del (p.Leu11Serfs*19), Hemizygous in Proband [III-1].
- Lineage Attribution: Exclusively MATERNAL LINEAGE transmission.
- Father [II-1] transmits his Y chromosome to Proband [III-1]; paternal transmission of an X-linked 
  allele to a male child is biologically impossible.
- Mother [II-2] is a confirmed Heterozygous Carrier (obligate carrier from affected father [I-1]).
- Phenotypic Synthesis: Mother's mild muscle weakness is explained by SKEWED X-INACTIVATION 
  (Lyonization), where the wild-type X chromosome is preferentially inactivated in skeletal myocytes.
- Recurrence Risk: Future male offspring of Mother [II-2] face a 50% risk of full disease manifestation;
  future female offspring face a 50% risk of carrier status.
====================================================================================================
```

---

## 9. Deep-Dive Clinical Case Study 4: De Novo Mutation Discrimination

```text
====================================================================================================
CLINICAL CASE REPORT: FAM_DENOVO_019
====================================================================================================

PEDIGREE CONTEXT:
Child [II-1] presents with severe early-infantile epileptic encephalopathy (Dravet Syndrome).
Targeted panel reveals heterozygous SCN1A c.2837G>A (p.Arg946His).
Both biological parents undergo certified high-coverage (60x) Whole Genome Sequencing.

MODEL DEDUCTIVE REASONING (EXCERPT):
- Proband [II-1]: Confirmed Heterozygous SCN1A c.2837G>A (Variant Present).
- Father [I-1]: Confirmed Homozygous Wild-Type (0 reads alt / 68 reads ref) -> VERIFIED_ABSENT.
- Mother [I-2]: Confirmed Homozygous Wild-Type (0 reads alt / 72 reads ref) -> VERIFIED_ABSENT.
- Biological Parentage: Certified using 24-marker STR paternity/maternity panel (P > 0.99999).
- DEDUCTIVE CONCLUSION:
  * The variant is classified as a DE NOVO GERMLINE MUTATION.
  * Transmission Lineage: Non-inherited; arose during gametogenesis in parental germline or post-zygotic.
  * Recurrence Risk: Low (~1-2%), primarily driven by the theoretical probability of low-level 
    parental germline mosaicism not detectable in peripheral blood lymphocytes.
====================================================================================================
```

---

## 10. Deep-Dive Clinical Case Study 5: Resolving Conflicting Laboratory Reports

```text
====================================================================================================
CLINICAL CASE REPORT: FAM_CONFLICT_007
====================================================================================================

CASE CONFLICT DESCRIPTION:
Two accredited laboratories issued discordant interpretations for TP53 c.743G>A in Proband [II-1]:
- Laboratory Alpha (2021): Classified as VARIANT OF UNCERTAIN SIGNIFICANCE (VUS).
- Laboratory Beta (2024): Classified as PATHOGENIC (citing updated functional transactivation assays).

MODEL REASONING GENERATION (VERBATIM EXCERPT):
----------------------------------------------------------------------------------------------------
"DISCREPANCY DETECTION ALERT:
The familial record contains mutually conflicting clinical assertions regarding TP53 c.743G>A.
- Lab Alpha (Report: #AL-2021) asserts: VUS (Criteria applied: PM2_Supporting, PP3).
- Lab Beta (Report: #BE-2024) asserts: PATHOGENIC (Criteria applied: PS3_VeryStrong, PM2, PP3).

EPISTEMIC STATE: CONFLICTING_UNRESOLVED.
The system CANNOT deterministically adopt a single pathogenicity status. The model maintains 
the variant under Epistemic Tier: CONFLICTING. 

CLINICAL RECOMMENDATION:
Prioritize the more recent (2024) evaluation by Laboratory Beta, which incorporated functional assay 
data from Kato et al. and the updated ClinGen TP53 Expert Panel guidelines. Case flagged for 
mandatory clinical geneticist arbitration before updating familial cancer surveillance protocols."
----------------------------------------------------------------------------------------------------
```

---

## 11. Deep-Dive Clinical Case Study 6: Epistemic Management of Missing Family Members

```text
====================================================================================================
CLINICAL CASE REPORT: FAM_MISSING_099
====================================================================================================

PEDIGREE CONTEXT:
Child [III-1] carries heterozygous pathogenic variant in RET (c.1892G>A, p.Cys631Tyr) associated 
with Multiple Endocrine Neoplasia Type 2A (MEN2A).
Father [II-1] was killed in an automobile accident at age 24 and was NEVER genotyped.
Paternal Grandfather [I-1] had medullary thyroid carcinoma at age 45 (genotyping never performed).
Mother [II-2] tests verified Wild-Type (WT/WT).

MODEL DEDUCTIVE REASONING (EXCERPT):
- Proband [III-1]: RET c.1892G>A (Heterozygous) -> VERIFIED_PRESENT.
- Mother [II-2]: RET c.1892G>A -> VERIFIED_ABSENT (Ruled out as transmitting parent).
- Father [II-1]: RET c.1892G>A -> STRICT_UNKNOWN (Deceased, ungenotyped).
- Paternal Grandfather [I-1]: Clinical history present; Genotype -> STRICT_UNKNOWN.
- EPISTEMIC DEDUCTIVE CONCLUSION:
  * While paternal phenotypic history strongly suggests paternal transmission, Father [II-1] 
    CANNOT be formally declared a verified carrier.
  * The model records Father [II-1] as an OBLIGATE SUSPECTED CARRIER with status: STRICT_UNKNOWN.
  * System explicitly evaluates the competing hypothesis: De novo mutation in Proband [III-1].
  * Clinical Action: Recommend post-mortem DNA extraction from archival tissue blocks for [II-1] if 
    available, or cascade screening of surviving paternal siblings (paternal aunts/uncles).
====================================================================================================
```

---

## 12. Ethical Disease-Risk Boundaries and Penetrance Non-Determinism

A paramount ethical rule of GenInherit-LLM is the **rejection of genetic fatalism**. The model is structurally constrained from generating definitive claims of future disease development:

```text
+--------------------------------------------------------------------------------------------------+
|                              THE NON-DETERMINISM ETHICAL MATRIX                                  |
+--------------------------------------------------------------------------------------------------+

  GENETIC DETERMINISM (STRICTLY FORBIDDEN):
  [FAIL] "Because Proband [III-1] inherited the BRCA1 c.68_69delAG variant, she WILL develop breast 
         cancer at age 45."
         -> VIOLATION: Ignores incomplete penetrance, environmental factors, and prophylactic care.

  CALIBRATED BIOLOGICAL REASONING (CLINICALLY ENFORCED):
  [PASS] "Proband [III-1] has inherited the pathogenic BRCA1 c.68_69delAG variant via the maternal 
         lineage. In female carriers, this variant is associated with an estimated 55% to 72% cumulative 
         lifetime risk of breast carcinoma and a 39% to 44% lifetime risk of ovarian carcinoma. 
         Disease development is MODULATED by incomplete penetrance, polygenic modifier background, 
         and lifestyle factors. This finding warrants enhanced clinical surveillance as outlined in 
         NCCN Genetic/Familial High-Risk Assessment Guidelines."
+--------------------------------------------------------------------------------------------------+
```

### 12.1 Mathematical Formulation of Familial Penetrance Bounds

Let $P(\text{Disease} \mid G)$ represent the lifetime penetrance of genotype $G$. The model expresses disease probability as an interval bounded by familial modifiers:

$$P\left(\text{Phenotype Manifestation} \mid G_{\text{proband}}, \mathcal{P}_{\text{family}}\right) \in \left[ \gamma_{\text{population}}, \, \gamma_{\text{familial\_observed}} \right]$$

Where the model explicitly outputs the uncertainty bounds rather than a single deterministic prediction.

---

## 13. Epistemic Vocabulary Enforcement: Observed vs. Inferred vs. Unknown

The safety filter scans all token emissions to verify conformance with formal epistemic vocabulary prefixes:

```text
====================================================================================================
                        EPISTEMIC PREFIX REGULATORY TAXONOMY
====================================================================================================
PREFIX TAG              PERMITTED CLINICAL CONTEXT
----------------------------------------------------------------------------------------------------
[OBSERVED_LAB]          Applied exclusively to facts directly verified by a certified laboratory assay.
                        Example: "[OBSERVED_LAB] Father II-1 is heterozygous for c.1504C>T."

[OBSERVED_CLINICAL]     Applied to clinician-confirmed phenotypic diagnoses recorded in the chart.
                        Example: "[OBSERVED_CLINICAL] Proband diagnosed with aortic dilatation."

[INFERRED_MENDELIAN]    Applied to mathematical deductions derived from pedigree topological logic.
                        Example: "[INFERRED_MENDELIAN] Grandfather I-1 is an obligate carrier."

[ASSOCIATED_LITERATURE] Applied to public knowledgebase assertions regarding disease validity.
                        Example: "[ASSOCIATED_LITERATURE] MYBPC3 is definitively associated with HCM."

[STRICT_UNKNOWN]        Mandatory tag whenever clinical or molecular evidence is missing.
                        Example: "[STRICT_UNKNOWN] Maternal grandmother's genotype has never been tested."
====================================================================================================
```

---

## 14. Institutional Clinical Workflow Integration

```text
HOSPITAL CLINICAL GENETICS CASE CONFERENCE WORKFLOW
====================================================================================================
Time 08:30 : Genetic Counselor prepares weekly undiagnosed pediatric case conference.
             - Ingests Proband VCF + 3-Generation Pedigree into GenInherit-LLM portal.
             - System executes validation pipeline; attaches to Family Adapter `Fam_381_v2`.

Time 08:35 : Counselor queries: "Deduce possible inheritance modes for proband's syndromic epilepsy."
             - Model outputs 10-tier structured analysis:
               * Highlights compound heterozygous variants in POLG.
               * Identifies that Variant 1 was inherited from asymptomatic Father.
               * Discovers that Variant 2 has NO maternal sequencing on record (`STRICT_UNKNOWN`).

Time 09:15 : Multidisciplinary Clinical Board convenes (Genetics, Neurology, Pathology).
             - Board reviews GenInherit-LLM reasoning trace displayed on conference monitor.
             - Attending Geneticist notes: "Model correctly identified that we cannot declare 
               compound heterozygosity in trans until we confirm Mother carries Variant 2."

Time 09:30 : Actionable Clinical Order Placed:
             - Board orders maternal targeted Sanger sequencing for POLG exon 17.
             - Model draft narrative is imported into Epic EHR as a "Clinical Case Conference Note"
               after manual digital signature by Dr. Vance, FACMG.
====================================================================================================
```

---

## 15. Academic Research and Cohort Simulation Workflow

For academic institutions studying complex inheritance (e.g., oligogenic inheritance, modifier genes):
1. **Synthetic Cohort Generation:** Researchers instantiate 1,000 synthetic family adapters using simulated pedigree generators (e.g., PedDesign, SimPed).
2. **Systematic Incomplete Penetrance Simulation:** Researchers vary penetrance from $10\%$ to $90\%$ and measure the model’s ability to correctly deduce transmission despite phenotypic skips.
3. **Benchmarking Against BBNs:** Deductive reasoning proofs are scored against traditional Bayesian networks to validate causal explanation quality.

---

## 16. Medical Education and Student Sandbox Protocol

To train medical students and genetic counseling fellows:
* **The Sandbox Interface:** Students are given a web portal connected to a designated educational instance of GenInherit-LLM (running Mode A).
* **Interactive Counterfactual Querying:**
  * Student input: *"What happens to the inheritance probability if I change the maternal grandmother from wild-type to affected?"*
  * Model response: Instantly recomputes the multi-hop proof, explaining how the transmission switches from a suspected de novo event to maternal autosomal dominant transmission with incomplete penetrance.

---

## 17. The Family-Mediated Interface Protocol

To protect patients from psychological distress, families access GenInherit-LLM exclusively through a **Clinician-Mediated Portal**:

```text
                     +---------------------------------------+
                     |        GENINHERIT-LLM PLATFORM        |
                     +---------------------------------------+
                                         |
                                         v
                     +---------------------------------------+
                     |    CLINICAL GENETICIST REVIEW DESK    |
                     |  (Board-certified review of draft)    |
                     +---------------------------------------+
                                         |
                                  [Doctor Signs Off]
                                         |
                                         v
                     +---------------------------------------+
                     |       PATIENT-FACING FAMILY PORTAL    |
                     |   (Jargon-Free, Calibrated Explanations|
                     |    Coupled with Counselor Contact)    |
                     +---------------------------------------+
```

---

## 18. End-to-End System Processing Flowchart

The following comprehensive sequence traces the lifecycle of a clinical query:

```text
USER                  API GATEWAY          ADAPTER ROUTER       GPU ENGINE (B200)      VALIDATOR & AUDIT
 |                         |                     |                      |                      |
 |--- Submit Query ------->|                     |                      |                      |
 |    (JWT + Family ID)    |--- Check RBAC ----->|                      |                      |
 |                         |    & Decrypt Token  |                      |                      |
 |                         |                     |--- Fetch Adapter --->|                      |
 |                         |                     |    (FAM_042_v3.bin)  |                      |
 |                         |                     |                      |                      |
 |                         |--- Build Context ------------------------->|                      |
 |                         |    (PSTS-v1 Tokens + Prompts)              |                      |
 |                         |                     |                      |                      |
 |                         |                     |                      |-- Autoregressive --->|
 |                         |                     |                      |   Transformer Pass   |
 |                         |                     |                      |                      |
 |                         |<-------------------- Raw Tokens -----------|                      |
 |                         |                                                                   |
 |                         |--- Verify Grammar & Epistemic Tags ------------------------------>|
 |                         |                                                                   |
 |                         |<-- Schema Validated & Signed -------------------------------------|
 |                         |                                                                   |
 |<-- Return Proof --------|                                                                   |
 |    (10-Tier Markdown)   |                                                                   |
```

---

## Summary of Volume 4

In this volume, we have specified:
1. The inference engine pipeline, including context assembly and sub-second adapter dispatch.
2. The four core cognitive functions: Fact Recall, Family Mapping, Inheritance Reasoning, and Causal Explanation.
3. The standardized 10-tier structured output schema.
4. Six comprehensive clinical case studies covering autosomal dominant, recessive/consanguinity, X-linked/Lyonization, de novo mutation, conflicting lab resolution, and missing data management.
5. The ethical non-determinism boundaries and epistemic vocabulary enforcement.
6. Institutional deployment workflows for hospitals, research labs, medical schools, and clinician-mediated patient portals.

*The architectural specification concludes in **Volume 5: Evaluation Framework, Security, Privacy, and Governance**.*
